Reimagining RNA medicine

May 18, 2026

Wave Life Sciences Announces Positive Update on RestorAATion-2 Trial: WVE-006 (GalNAc-RNA Editing) Achieves MZ-Like Phenotype Across Both Biweekly and Monthly Dosing

May 13, 2026

Wave Life Sciences to Present at 2026 RBC Capital Markets Global Healthcare Conference

Apr 28, 2026

Wave Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Update

Apr 22, 2026

Wave Life Sciences First Quarter 2026 Financial Results Scheduled for April 28, 2026

Apr 21, 2026

Wave Life Sciences Announces Hearing on Proposed Redomiciliation to the United States

Apr 15, 2026

Wave Life Sciences Announces Proposed Redomiciliation to the United States

Mar 26, 2026

Wave Life Sciences Announces Positive Interim Phase 1 Data from INLIGHT: Further Improvements in Body Composition, with Clinically Meaningful Reductions in Visceral Fat and Waist Circumference, at Six Months Following Single Dose of WVE-007

Mar 05, 2026

Wave Life Sciences Announces Acceptance of Late-Breaking Oral Presentation on WVE-006 for Alpha-1 Antitrypsin Deficiency at the American Thoracic Society International Conference

Feb 26, 2026

Wave Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Feb 23, 2026

Wave Life Sciences to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference